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A B S T R A C T
Purpose
Most patients with breast cancer age  65 years (ie, older patients) are eligible for adjuvant
hormonal therapy, but use is not universal. We examined the influence of frailty on hormonal
therapy noninitiation and discontinuation.
Patients and Methods
A prospective cohort of 1,288 older women diagnosed with invasive, nonmetastatic breast cancer
recruited from 78 sites from 2004 to 2011 were included (1,062 had estrogen receptor–positive
tumors). Interviews were conducted at baseline, 6 months, and annually for up to 7 years to collect
sociodemographic, health care, and psychosocial data. Hormonal initiation was defined from
records and discontinuation from self-report. Baseline frailty was measured using a previously
validated 35-item scale and grouped as prefrail or frail versus robust. Logistic regression and
proportional hazards models were used to assess factors associated with noninitiation and
discontinuation, respectively.
Results
Most women (76.4%) were robust. Noninitiation of hormonal therapy was low (14%), but in
prefrail or frail (v robust) women the odds of noninitiation were 1.63 times as high (95% CI, 1.11
to 2.40; P  .013) after covariate adjustment. Nonwhites (v whites) had higher odds of
noninitiation (odds ratio, 1.71; 95% CI, 1.04 to 2.80; P  .033) after covariate adjustment. Among
initiators, the 5-year continuation probability was 48.5%. After adjustment, the risk of discontin-
uation was higher with increasing age (P  .005) and lower for stage  IIB (v stage I) disease (P 
.003).
Conclusion
Frailty is associated with noninitiation of hormonal therapy, but it does not seem to be a major
predictor of early discontinuation in older patients.
J Clin Oncol 32:2318-2327. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Women age  65 years (ie, older patients) consti-
tute nearly half of patients with breast cancer.1,2
This group will account for an increasing absolute
number of patient cases over the coming decades
because of the aging of the US population. Most of
these older women (approximately 70%) will
have estrogen receptor (ER) –positive breast
cancers.3-5 Adjuvant hormonal therapy decreases
recurrence6 and breast cancer–specific mortality
in ER-positive cancers.6
Current guidelines recommend that women
with ER-positive disease receive adjuvant hormonal
therapy for at least 5 years,7 but older women have
been found to initiate therapy less often and discon-
tinue treatment more frequently than younger
women.4,8-10 Factors similar to those noted for
younger women4,11 also affect older women’s use of
hormonal treatment, including patient attitudes,12
difficulties in discussing treatment with providers,3
and financial barriers.13
A unique aspect of treatment in older patients
is the considerable heterogeneity in functional sta-
tus, level of comorbidity, accumulated health defi-
cits, and probability of competing causes of
death.14,15 The concept of frailty has been used to
capture these domains as distinct from chronologic
age.16 However, most prior investigations of nonini-
tiation and discontinuation have been based on data
available in tumor registries or administrative data-
bases and have only captured limited data on
frailty.8,9,13,17 Frailty might affect patterns of hor-
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monal therapy use and the balance of its risks and benefits. We used
data from a large national prospective cohort of older patients
with breast cancer to examine whether baseline frailty influ-
enced noninitiation and discontinuation of hormonal therapy
independent of chronologic age. We also explored whether
sociodemographic characteristics and health care interactions
affected hormonal therapy patterns.
PATIENTS AND METHODS
This analysis used data from a national cohort study of patterns of systemic
therapy in older women.18,19 The study was conducted at 78 hospitals or
practices affiliated with the Cancer and Leukemia Group B (CALGB) cooper-
ative group, presently part of the Alliance for Clinical Trials in Oncology.18 The
protocol met Health Insurance Portability and Accountability Act standards
and was approved by CALGB and the institutional review boards at all sites.
Population
Participants were registered between January 1, 2004, and April 1, 2011.
Eligible participants were age  65 years, diagnosed with invasive ( 1 cm)
nonmetastatic breast cancer, spoke English or Spanish, and had sufficient
cognitive function to complete interviews.20,21 Women were  20 weeks from
their last definitive surgery and had not initiated hormonal therapy. There
were 1,703 women registered for the study (Fig 1); of these, 1,526 were eligible.
A total of 1,288 baseline interviews (84.4%) were completed. This analysis was
restricted to women with ER-positive tumors (n  1,062).
Data Collection
Clinical research associates assessed patients, confirmed eligibility, ob-
tained consent, and performed record review, including determination of ER
status using standard criteria. Patients completed a 45-minute baseline struc-
tured telephone interview. Anchored on the baseline interview date, patients
completed 15- to 20-minute follow-up interviews at 6 months and annually
thereafter for up to 7 years.
Measures
Outcomes were noninitiation and discontinuation of adjuvant hor-
monal therapy over 5 years (recommended duration during study period).
Initiation of any type of adjuvant hormonal therapy (and start date) was based
on medical records. Discontinuation was based on patient self-report. The
stopping or censoring date was set at the midpoint between consecutive inter-
views.22 Women who died or experienced recurrence were censored at the date
of the event based on medical records. Women who stopped  18 months
before the recurrence date were classified as discontinuing.
Frailty, the primary predictor, was measured by adapting the 35-item
scale (Appendix Table A1, online only) developed by Searle et al,23 previously
validated to predict mortality in community-dwelling elders. It includes self-
reported items relating to limitations in basic and instrumental activities of
daily living, sensory deficits, functioning, and prediagnosis comorbidity. Be-
cause we excluded women with cognitive impairment, this item was not
included in our adaptation. To evaluate the separate contributions of age and
frailty, age was not included.23,24 Each deficit item was rated between 0 and 1,
where a higher score indicated greater frailty (Cronbach’s   0.77). Scores
were calculated for participants missing  10% of items (1% missing  10%;
Appendix, online only). Values for nonmissing items were summed and di-
vided by the total number of items, yielding a final score between 0 and 1; four
deficits necessitated scoring of intermediate levels, and weights were applied
per published methods.23 Frailty scores were categorized based on cut points
related to mortality outcomes16,23 as follows: robust, 0 to  0.2; prefrail, 0.2
to  0.35; and frail  0.35 to 1. Given the sample distributions, we collapsed
groupings into robust versus prefrail or frail.
Other selected measures were based on the adherence model of health
behavior25,26 and included sociodemographic, psychosocial, attitudinal,
patient-provider interaction, health care setting, and clinical (surgery,
American Joint Committee on Cancer [version 6] stage, and chemotherapy
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Fig 1. Study sample of older women
with estrogen receptor (ER) –positive
breast cancer. (*) A total of 1,703 partici-
pants were registered for the study. This
is a correction from a 2012 publication
indicating 1,704 participants.18 A duplicate
entry for a participant was deleted; prior anal-
yses only included this individual once.
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Sociodemographic factors included age, marital status, and race (white v
nonwhite). As a proxy for wealth, we assessed education, insurance, prescrip-
tion drug coverage, and home ownership. Psychosocial and attitudinal factors
included perceived ageism in cancer care (eg, “physicians treat older women
[age  65 years] and younger women [age  65 years] the same”;   0.81),27
fatalism (eg, “if someone is meant to get breast cancer, she will get it no matter
what she does”;   0.58),28 optimism (eg, “I hardly expect things to go my
way”;   0.72),29 and emotional (  0.96) and tangible (  0.93) support
subscales of the Medical Outcomes Study scale.30
Patient perceptions of patient-physician communication were assessed
using the Makoul scale and Primary Care Assessment Survey (PCAS). The
seven-item Makoul scale31 addresses the role of patients and providers during
information exchange (eg, “physician gave me all of the information I needed
about my breast cancer”;   0.80). Patients’ ratings of provider communica-
tion were also assessed with PCAS items (eg, “how often did you leave your
physician’s office with unanswered questions?”   0.95).32 Other PCAS
subscales, including patients’ ratings of the medical oncologists’ knowledge
about them (  0.84), interpersonal treatment (eg, “physician’s caring and
concern”;   0.96), and thoroughness of examinations (eg, “thoroughness of
physician’s physical examination of you”) and trust (eg, “I completely trust my
physician’s judgments about my medical care”;   0.78), were added to the
survey in 2008 and were not available for all women. Factors related to setting
of care included health maintenance organization (yes v no) and National
Cancer Institute–designated comprehensive cancer center status (yes v no).
Statistical Analysis
Univariable associations between hormonal noninitiation and variables
of interest were assessed using t and 2 tests. Variables related to noninitiation
at a level of P  .10 were considered in the multivariable logistic regression
model. Frailty was included as the main predictor, whereas age, race, and stage
were retained for face validity regardless of statistical significance. Backward
elimination using a significance level of P  .05 was used to determine the final
model. Model fit was assessed using the Hosmer-Lemeshow goodness-of-
fit test.
We used Kaplan-Meier survival curves to estimate the probability of
continuation over time overall and for subgroups of interest (eg, by frailty
category). The log-rank test was used to compare the distributions of time with
discontinuation between groups of interest. Cox proportional hazards models
assessed the univariable relationships between time to discontinuation and
covariates. Patients were censored at death (n  23). We included patients
with recurrent disease (n  54); 41 were censored at the time or date of
recurrence, and 13 were classified as nonadherent because they discontinued
therapy  18 months before their recurrence date. On the basis of routine
clinical treatment and diagnostic timeframes, the 18-month window was se-
lected so as not to count women who stopped therapy because of a recurrence
as having discontinued therapy prematurely. We used the 18-month window
as a conservative approach, because we had dates of recurrence from records,
whereas dates of hormonal therapy discontinuation were based on self-report
in annual interviews.
Variable selection for inclusion in the multivariable hazards model was
based on a significance level of .10 in univariable analysis. Backward elimina-
tion at the .05 significance level was used to determine the final Cox propor-
tional hazards regression model; frailty index was included in the final model
as the main predictor. We used Kolmogorov-type supremum tests to test the
proportional hazards assumption for each variable included in the final
model.33 A competing-risk analysis was not performed, given the small num-
ber of women who died or experienced recurrence and to enhance the com-
parability of our results to those of related studies.
Variables related to health care interactions were statistically significant
in univariable analyses, so a sensitivity analysis was performed among partic-
ipants with data on these PCAS items (n  660; ie, those enrolled after survey
was modified in late 2008); using backward elimination, we ended up with the
same final model. We also used the Kaplan-Meier method to examine whether
patterns of discontinuation were similar for women receiving tamoxifen and
aromatase inhibitors. Analyses were conducted using SAS software (version
9.3; SAS Institute, Cary, NC).
RESULTS
Participants’ ages ranged from 65 to 91 years (mean, 72.8  standard
deviation, 6.05 years). Most had prescription coverage and owned
their own home (Table 1). The average frailty score was 0.14 ( stan-
dard deviation, 0.10). Overall, 76.4% had scores in the robust range (0
to  0.2); 18.7% were considered prefrail (0.2 to  0.35); only 4.9%
were considered frail ( 0.35; Table 1).
Noninitiation of Hormonal Therapy
The rate of noninitiation of adjuvant hormonal therapy was 14%.
Among those who initiated, 79% received an aromatase inhibitor, and
21% received tamoxifen or another selective ER modulator (Table 2).
Several factors were related to noninitiation of treatment in univari-
able analyses (Table 1), including age (odds ratio [OR], 1.04; 95% CI,
1.01 to 1.07 per 1-year increase; P. 007), nonwhite race (v white; OR,
1.69; 95% CI, 1.04 to 2.75; P  .034), and frailty or prefrailty versus
robustness (OR, 1.77; 95% CI, 1.21 to 2.58; P . 003). There was a
trend toward Medicare prescription coverage being related to treat-
ment initiation. Neither patient-provider nor clinical factors were
related to initiation of hormonal therapy. In multivariable analyses
(Table 1), age and race remained significant. The odds of noninitiation
were also higher in the prefrail or frail group (OR, 1.63; 95% CI, 1.11 to
2.40; P. 013) compared with the robust group, after considering age,
race, and stage.
Discontinuation of Hormonal Therapy
The median follow-up time from initiation was 3 years (range,
0.5 to 7 years). The continuation rate by 5 years was 48.5% and was
slightly lower among the frail group than the robust group (41% v
50%; log-rank P  .045; Fig 2). In univariable analyses (Table 2), the
point estimate for frailty suggested a trend toward a higher risk of
discontinuing therapy among prefrail or frail women compared with
robust women (hazard ratio, 1.32; 95% CI, 0.99 to 1.78; P  .060).
Several variables were significantly associated with discontinuation in
univariable analyses, including older age, being unmarried, not own-
ing a home, perceiving more ageism, being less optimistic, and having
less emotional and tangible support. Disease stage  IIB (v I) was
associated with continuing therapy. Also, chemotherapy was inversely
associated with discontinuation. Continuation curves from the
Kaplan-Meier method (exploratory analysis; log-rank P  .076) did
not suggest evidence of statistical differences with respect to discon-
tinuation between women receiving tamoxifen versus those receiving
aromatase inhibitors (data not shown).
Among the subset who were asked about health care interactions,
features of the patient-oncologist relationship (eg, trust in physician
and so on) were associated with discontinuation in univariable analy-
ses, with those who rated the oncologist’s thoroughness, knowledge of
the patient, and trustworthiness higher (v lower) being less likely to
discontinue treatment (P  .05). After considering covariates, frailty
became nonsignificant (hazard ratio, 1.24; 95% CI, 0.92 to 1.67; P .
150). However, the direction of the point estimate remained similar to
unadjusted estimates (Table 2).
DISCUSSION
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Noninitiation of Hormonal Therapy (n  1,051)No
(n  149)
Yes
(n  913) Unadjusted Adjusted
No. % No. % No. % OR 95% CI P OR 95% CI P
Age, years† 1.04 1.01 to 1.07 .007 1.03 1.00 to 1.06 .029
Mean 72.78 74.02 72.57
SD 6.05 6.73 5.89
65-74 680 64.0 83 55.7 597 65.4
75-79 225 21.2 31 20.8 194 21.2
 80 157 14.8 35 23.5 122 13.4
Race
White 945 89.0 125 83.9 820 89.8 Referent
Nonwhite 117 11.0 24 16.1 93 10.2 1.69 1.04 to 2.75 .034 1.71 1.04 to 2.80 .033
Marital status
Married 596 56.4 74 49.7 522 57.6 Referent
Not married 460 43.6 75 50.3 385 42.4 1.37 0.97 to 1.94 .073
Missing 6 0 6
Home ownership
Yes 917 86.5 125 83.9 792 86.9 Referent
No 143 13.5 24 16.1 119 13.1 1.28 0.79 to 2.06 .314
Missing 2 0 2
Insurance
Medicare plus private 818 77.0 111 74.5 707 77.4 Referent
Medicare plus Medicaid 129 12.1 18 12.1 111 12.2 1.03 0.60 to 1.77 .690
Medicare only 115 10.8 20 13.4 95 10.4 1.34 0.80 to 2.26 .325
HMO
No 885 83.6 125 85.6 760 83.2 1.20 0.73 to 1.96 .473
Yes 174 16.4 21 14.4 153 16.8 Referent
Missing 3 3 0
Medicare Part D or insurance drug coverage
Yes 794 74.8 102 68.5 692 75.8 Referent
No 268 25.2 47 31.5 221 24.2 1.44 0.99 to 2.10 .057
Education, years
 12 614 57.8 91 61.1 523 57.3 Referent
 12 448 42.2 58 38.9 390 42.7 0.85 0.60 to 1.22 .385
Setting of care
Community 762 71.8 109 73.2 653 71.6 Referent
Cancer center 299 28.2 40 26.8 259 28.4 0.93 0.63 to 1.37 .696
Surgery
Lumpectomy 729 68.7 105 70.5 624 68.4 Referent
Mastectomy 332 31.3 44 29.5 288 31.6 0.91 0.62 to 1.33 .617
Missing 1 0 1
AJCC-6 stage
I 507 47.7 74 49.7 433 47.4 Referent
IIA 325 30.6 41 27.5 284 31.1 0.84 0.56 to 1.27 .381 0.83 0.55 to 1.26 .393
 IIB 230 21.7 34 22.8 196 21.5 1.02 0.65 to 1.58 .641 0.96 0.61 to 1.51 .857
Chemotherapy
No 707 67.1 98 67.6 609 67.1 Referent
Yes 346 32.9 47 32.4 299 32.9 0.98 0.67 to 1.42 .903
Missing 9 4 5
Frailty score‡
Robust 803 76.4 98 66.7 705 78.0 Referent
Prefrail 197 18.7 35 23.8 162 17.9 1.77 1.21 to 2.58 .003 1.63 1.11 to 2.40 .013
Frail 51 4.9 14 9.5 37 4.1
Missing 11 2 9
Communication 1.03 0.81 to 1.30 .833
Mean 4.17 4.19 4.17
SD 0.75 0.74 0.76
Missing 68 14 54
(continued on following page)
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hormonal therapy, but nearly half discontinued treatment before 5 years.
Advancing age was related to noninitiation and discontinuation of adju-
vant hormonal therapy. Even after considering chronologic age, women
who were frail or prefrail tended to have higher odds of noninitiation. We
didnotfindasignificantrelationshipbetweendiscontinuationandfrailty.
Nonwhite race played a larger role in noninitiation than in discontinua-
tionoftherapy.Typeofregimen,attitude,psychosocial factors,andhealth
care interactions were not consistently associated with noninitiation or
discontinuation in this sample.
The rate of initiation that we observed was higher than those in
prior reports3,34 and may reflect the fact that this cohort was recruited
from a cooperative group setting. The rates of discontinuation
in this population were similar to those reported in other
older cohorts.8,9,17,35
Although prior studies have considered age,3,8,9,12,13,17 comor-
bidity,3,8,9,12,17 or functional status,3,12 none have included the multi-
dimensional construct of frailty.36 Frailty encompasses daily
functioning, physiologic, cognitive, and emotional reserves. Although








Noninitiation of Hormonal Therapy (n  1,051)No
(n  149)
Yes
(n  913) Unadjusted Adjusted
No. % No. % No. % OR 95% CI P OR 95% CI P
Knowledge about patient§ 0.97 0.92 to 1.03 .317
Mean 21.52 20.90 21.58
SD 4.99 4.98 4.98
Missing 327 91 236
Thoroughness of care§ 1.03 0.77 to 1.37 .837
Mean 5.23 5.25 5.23
SD 0.94 0.78 0.95
Missing 319 90 229
Trust in physician§ 0.94 0.88 to 1.02 .125
Mean 28.39 27.73 28.45
SD 3.45 4.12 3.39
Missing 317 89 228
Optimism 0.93 0.73 to 1.18 .548
Mean 4.25 4.22 4.26
SD 0.74 0.74 0.74
Missing 30 7 23
Ageism 0.98 0.90 to 1.07 .670
Mean 5.01 4.93 5.02
SD 2.26 2.30 2.26
Missing 150 26 124
Fatalism 0.91 0.67 to 1.24 .567
Mean 0.28 0.25 0.28
SD 0.63 0.58 0.63
Missing 73 17 56
Emotional support 1.00 0.79 to 1.27 .988
Mean 4.34 4.34 4.34
SD 0.76 0.81 0.75
Missing 52 13 39
Tangible support 0.94 0.76 to 1.16 .543
Mean 4.41 4.37 4.42
SD 0.83 0.91 0.82
Missing 54 13 41
Treatment communication 1.01 0.97 to 1.06 .567
Mean 45.07 45.43 45.03
SD 5.66 5.22 5.71
Missing 266 74 192
NOTE. Bold font indicates statistical significance (P  .05; excluding race and age).
Abbreviations: AJCC-6, American Joint Committee on Cancer (version 6); HMO, health maintenance organization; OR, odds ratio; PCAS, Primary Care Assessment
Survey; SD, standard deviation.
Blank cells indicate variable was removed through backward elimination and not included in final regression model.
†Age was employed as continuous variable in unadjusted and adjusted models; results of Hosmer-Lemeshow test (P  .51) provided support for goodness-of-fit
of final logistic regression model.
‡Frailty was used as robust versus prefrail or frail in analysis.
§Item is PCAS subscale32 and was only added to patient interview in 2008, so data were not available for all participants in our sample; analyses using this variable
were conducted as sensitivity analyses.
Refers to patient involvement in communication about therapy.
Sheppard et al
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No. % No. % No. % HR 95% CI P HR 95% CI P
Age, years† 1.04 1.02 to 1.06 < .001 1.03 1.01 to 1.05 .005
Mean 72.57 73.12 72.34
SD 5.89 6.11 5.81
65-74 597 65.4 159 63.6 438 66.1
75-79 194 21.2 50 20.0 144 21.7
 80 122 13.4 41 16.4 81 12.2
Race
White 820 89.8 224 89.6 596 89.9 Referent
Nonwhite 93 10.2 26 10.4 67 10.1 1.26 0.84 to 1.89 .264 1.32 0.88 to 1.98 .182
Marital status
Married 522 57.6 135 54.4 387 58.7 Referent
Not married 385 42.4 113 45.6 272 41.3 1.32 1.03 to 1.69 .030
Missing 6 2 4
Home ownership
Yes 792 86.9 210 84.0 582 88.0 Referent
No 119 13.1 40 16.0 79 12.0 1.50 1.07 to 2.11 .018
Missing 2 0 2
Insurance
Medicare plus private 707 77.4 180 72.0 527 79.5 Referent
Medicare plus Medicaid 111 12.2 39 15.6 72 10.9 1.17 0.83 to 1.65 .380
Medicare only 95 10.4 31 12.4 64 9.7 1.23 0.84 to 1.79 .296
HMO
No 760 83.2 203 81.2 557 84.0 1.00 0.73 to 1.37 .996
Yes 153 16.8 47 18.8 106 16.0 Referent
Medicare Part D or insurance drug coverage
Yes 692 75.8 208 83.2 484 73.0 Referent
No 221 24.2 42 16.8 179 27.0 1.02 0.73 to 1.43 .911
Education, years
 12 523 57.3 152 60.8 371 56.0 Referent
 12 390 42.7 98 39.2 292 44.0 1.04 0.81 to 1.34 .770
Setting of care
Community 653 71.6 183 73.5 470 70.9 Referent
Cancer center 259 28.4 66 26.5 193 29.1 0.80 0.60 to 1.06 .114
Surgery
Lumpectomy 624 68.4 175 70.0 449 67.8 Referent
Mastectomy 288 31.6 75 30.0 213 32.2 0.98 0.75 to 1.28 .873
Missing 1 0 1
AJCC-6 stage
I 433 47.4 143 57.2 290 43.7 Referent Referent
IIA 284 31.1 71 28.4 213 32.1 0.75 0.57 to 1.00 .051 0.76 0.57 to 1.02 .064
 IIB 196 21.5 36 14.4 160 24.1 0.56 0.39 to 0.81 .002 0.57 0.39 to 0.82 .003
Chemotherapy
No 609 67.1 197 79.1 412 62.5 Referent
Yes 299 32.9 52 20.9 247 37.5 0.45 0.33 to 0.61 < .001
Missing 5 1 4
Type of hormonal therapy
Aromatase inhibitor 710 79.3 178 74.2 532 81.2 Referent
SERM 185 20.7 62 25.8 123 18.8 1.28 0.96 to 1.71 .094
Missing 18 10 8
Frailty score‡
Robust 705 78.0 189 76.2 516 78.7 Referent
Prefrail 162 17.9 51 20.6 111 16.9 1.32 0.99 to 1.78 .060 1.24 0.92 to 1.67 .150
Frail 37 4.1 8 3.2 29 4.4
Missing 9 2 7
(continued on following page)
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it is correlated with age,23 frailty is heterogeneous within age groups
and has been validated in multiple studies to predict nursing home
placement16 and mortality in older community populations.16,37 The
finding that women who were prefrail or frail initiated therapy less
often than robust women suggests that there may have been some
consideration of the balance of life expectancy and the probability of
recurrence within remaining life expectancy. We do not have data to
directly test this idea; however, if true, the relationship between higher
frailty and noninitiation could indicate that women and/or their pro-
viders are making informed judgments about the risks and benefits.
An alternative explanation is that women with greater frailty may have
been concerned about adverse effects based on interactions of hor-
monal therapy and specific comorbidities,38 such as cardio- and/or
cerebrovascular disease and risk of thromboembolic events.39 It is also










No. % No. % No. % HR 95% CI P HR 95% CI P
Communication 0.87 0.73 to 1.03 .116
Mean 4.17 4.14 4.18
SD 0.76 0.79 0.75
Missing 54 22 32
Knowledge of patient§ 0.97 0.94 to 0.99 .017
Mean 21.58 21.23 21.74
SD 4.98 5.19 4.87
Missing 226 35 201
Thoroughness of care§ 0.84 0.74 to 0.97 .016
Mean 5.23 5.15 5.27
SD 0.95 0.99 0.93
Missing 229 32 197
Trust in physician§ 0.94 0.90 to 0.98 .003
Mean 28.45 28.06 28.62
SD 3.39 3.42 3.37
Missing 228 33 195
Optimism 0.84 0.71 to 1.00 .048
Mean 4.26 4.22 4.27
SD 0.74 0.74 0.73
Missing 23 9 14
Ageism 1.07 1.01 to 1.13 .016
Mean 5.02 5.45 4.86
SD 2.26 2.47 2.16
Missing 124 36 88
Fatalism 1.05 0.85 to 1.31 .644
Mean 0.28 0.25 0.29
SD 0.63 0.63 0.63
Missing 56 17 39
Emotional support 0.84 0.72 to 1.00 .045
Mean 4.34 4.30 4.35
SD 0.75 0.82 0.73
Missing 39 13 26
Tangible support 0.85 0.73 to 0.98 .024
Mean 4.42 4.34 4.45
SD 0.82 0.88 0.79
Missing 41 13 28
Treatment communication 0.98 0.96 to 1.01 .159
Mean 45.03 44.52 45.27
SD 5.71 5.49 5.80
Missing 192 20 172
NOTE. Bold font indicates statistical significance (P  .05).
Abbreviations: AJCC-6, American Joint Committee on Cancer (version 6); HMO, health maintenance organization; HR, hazard ratio; PCAS, Primary Care
Assessment Survey; SD, standard deviation.
Blank cells indicate variable was removed through backward elimination and not included in final regression model.
†Age was employed as continuous variable in unadjusted and adjusted models; P values from tests of proportional hazards assumption (Kolmogorov-type
supremum tests) ranged from .13 to .55, providing support for proportional hazards assumption.
‡Frailty was used as robust versus prefrail or frail in analysis.
§Item is PCAS subscale32 and was only added to patient interview in 2008, so data were not available for all participants in our sample; analyses using this variable
were conducted as sensitivity analyses.
Refers to patient involvement in communication about therapy.
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possible that the primary treatment goal in older women, especially
frail patients, may be to avoid recurrence before death resulting from
other causes, because older women generally will not die as a result of
their breast cancers.40,41
Our data suggest that the frailest women never initiated therapy.
This may explain why frailty, while tending to be associated with
discontinuation, was not significant in the discontinuation analysis.
Overall, the frailty results imply that patterns of noninitiation may
reflect appropriate use of adjuvant therapy rather than suboptimal
quality of care for older women.35 With the increasing use of geriatric
assessment within the oncology setting,42-45 new senior adult oncolo-
gy recommendations from the National Comprehensive Cancer Net-
work,7 and the availability of easy-to-use prognostic indices that
generate life expectancy estimates,46 it should become easier to incor-
porate discussions about harms and benefits of cancer treatments into
routine clinical oncology care with older patients.
Our results also suggest that race was more important in nonini-
tiation than in discontinuation patterns of care. This finding is in
concert with others that found that nonwhites were less likely to
initiate therapy.34,47-49 However, Neugut et al4 did not find racial
differences in initiation in their sample of largely health maintenance
organization–insured women. Because we focused only on older
women in largely fee-for-service settings and had limited race variabil-
ity, this will be an important area for future investigation. It was
encouraging that when nonwhite women did initiate hormonal ther-
apy, they were no more likely to discontinue than whites.
Contrary to other reports,4,50 we did not find that type of hor-
monal regimen, attitudes about treatment, or patient-physician inter-
actions influenced noninitiation. We expected to see greater
discontinuation related to aromatase inhibitors compared with other
classes of therapy as a result of their higher reported musculoskeletal
adverse effects38 and potential interactions with arthritis and other
common comorbidities in older women. The similarity in patterns of
discontinuation for women receiving tamoxifen and aromatase inhib-
itors may indicate good tolerance of aromatase inhibitors in older
women. Alternatively, because most patients started on aromatase
inhibitors, we may not have been able to detect treatment-specific
effects. We also lacked data on whether women who started on tamox-
ifen switched to aromatase inhibitors over the follow-up period. Be-
cause a high rate of older women did ultimately discontinue hormonal
therapy, future investigation should consider regimen-specific ad-
verse effects, symptoms, and interactions with other illnesses.
Our data suggest that components of oncologist-patient interac-
tions were related to discontinuation. Unfortunately, for administra-
tive reasons, we only had data on a subset of the sample for these
measures, so we cannot draw conclusions about this important aspect
of adherence. Although several patient attitudes seemed important in
predicting discontinuation, they did not remain significant after con-
sidering age, frailty, and other factors. Of note, those with more ad-
vanced stage disease were less likely to discontinue, perhaps reflecting
communication about or understanding of greater potential benefits
versus risks.
Strengths of this study include its focus on older women, pro-
spective design, detailed patient-reported data, inclusion of key con-
structs posited to influence noninitiation and discontinuation of
hormonal therapy, and inclusion of frailty. Despite important
strengths, several caveats should be considered. First, this was a sec-
ondary analysis, so borderline levels of significance could represent
either lack of power or type I error resulting from examination of
multiple hypotheses. Although the results for frailty were suggestive,
these results should be confirmed in other studies. Next, hormonal
therapy initiation was based on medical records and confirmed
through self-report, but discontinuation was only measured via an-
nual self-report. Generally, the direction of any self-report bias has
been associated with an underestimation of the actual rates of early
discontinuation.51-53 However, previous reports found strong agree-
ment between self-report and pharmacy records12,22 and between
self-report and medical records.12,22,50,54 Because participants were
screened for cognitive status, and those with impairment were ex-
cluded, it is unlikely that there was systematic misclassification of
self-report by frailty index. Third, we only considered baseline frailty
(and not changes over time). Also, several factors could have limited
the representativeness and variability of the observed range of frailty
scores, including the exclusion of women with cognitive impairment,
healthy volunteer effects, and the cooperative group setting.18 These
constraints are likely to underestimate the true effects of frailty on
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Fig 2. Probability of continuing hormonal therapy over 5-year follow-up period
for older women with estrogen receptor (ER) –positive breast cancer (A) overall
and (B) by frailty level. Graphs are based on Kaplan-Meier curves for continuing
hormonal therapy among 885 women diagnosed from 2004 to 2011 with
ER-positive breast cancer who initiated hormonal therapy.
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cancer. Finally, the median length of follow-up of 3 years is also
a limitation.
This study illustrates the potential value of considering measures
of aging beyond chronologic age in understanding patterns of care for
older patients with cancer. Results suggest that consideration of frailty
for therapy initiation may be useful to clarify oncology treatment goals
and provide data for informed decision making about the balance of
benefits and risks of long-term cancer regimens among the growing
older patient population.44,55,56
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GLOSSARY TERMS
aromatase inhibitors: inhibitors used in treating breast
cancer in postmenopausal women. Aromatase inhibitors inhibit
the conversion of androgens to estrogens by the enzyme aroma-
tase, thus depriving the tumor of estrogenic signals. Because of
decreased production of estrogen, estrogen receptors, which are
important in the progression of breast cancer, cannot be
activated.
estrogen receptor (ER): ligand-activated nuclear proteins, belong-
ing to the class of nuclear receptors, present in many breast cancer cells
that are important in the progression of hormone-dependent cancers.
After binding, the receptor-ligand complex activates gene transcription.
There are two types of estrogen receptors (ER and ER). ER is one of
the most important proteins controlling breast cancer function. ER is
present in much lower levels in breast cancer, and its function is uncer-
tain. Estrogen receptor status guides therapeutic decisions in breast
cancer.
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Appendix
Frailty Measure
In this study, we adapted the frailty index of Searle et al23 to provide a patient self-reported measure of frailty. A total of 35 variables
were included in our adapted index, including self-reported items relating to baseline limitations in basic and instrumental activities of
daily living, existing sensory deficits, prediagnosis functioning, and prediagnosis comorbidity. Because we excluded women with cognitive
impairment, this item was not included in the index. We also did not include age, because we were interested in the contributions of frailty
beyond chronologic age to patterns of hormonal therapy use. As described in Appendix Table A1, each item was rated as 0 (no deficit), 0.5
(intermediate value of deficit), or 1 (deficit present) based on the original scale published by Searle et al. Note that in concert with Searle
et al, some items with intermediate values were weighted and resulted in a score of 1 or 0. An example would be the ratings for general
health (from excellent to poor). These items we applied scoring weights of frailty per Searle et al, methodology that resulted in an overall
score for most items of 0 or 1.
Scores were calculated for those missing  10% of items (1% missing  10%). As in the original scale, values for nonmissing items
were summed, divided by the total number of nonmissing items, and standardized to yield a final score between 0 and 1, where a higher
score indicates greater frailty. Frailty scores were also categorized based on cut points in the literature related to mortality outcomes:
robust, 0 to0.2; prefrail, 0.2 to0.35; and frail,  0.35 to 1.16,23 Given the distribution in the sample, we collapsed groupings into robust
versus prefrail or frail for analysis.
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Table A1. Items and Scoring for Frailty Index
Item Value Format Score
1. Can take bath/shower23† 1 Without help 0
2 With some help 1
3 Completely unable 1
2. Can dress/undress self 23† 1 Without help 0
2 With some help 1
3 Completely unable 1
3. Can get in/out of bed23† 1 Without help 0
2 With some help 1
3 Completely unable 1
4. Can walk23† 1 Without help 0
2 With some help 1
3 Completely unable 1
5. Health limits moderate activities23† 1 Yes, limited a lot 0
2 Yes, limited a little 1
3 No, not limited at all 1
6. Can eat23† 1 Without help 0
2 With some help 1
3 Completely unable 1
7. Take care of own appearance23† 1 Without help 0
2 With some help 1
3 Completely unable 1
8. Trouble getting to bathroom on time† 1 No 0
2 Yes 1
3 Have catheter or colostomy 1
9. Health limits climbing stairs23† 1 Yes, limited a lot 0
2 Yes, limited a little 1
3 No, not limited at all 1
10. Can go shopping for groceries or clothes23† 1 Without help 0
2 With some help 1
3 Completely unable 1
11. Can do housework23† 1 Without help 0
2 With some help 1
3 Completely unable 1
12. Can prepare own meals23† 1 Without help 0
2 With some help 1
3 Completely unable 1
13. Can take own medicine23† 1 Without help 0
2 With some help 1
3 Completely unable 1
14. Can handle own money23† 1 Without help 0
2 With some help 1
3 Completely unable 1
15. General health‡ 1 Excellent 0




16. Physical health limits work or activities‡ 1 Yes, limited a lot 1
2 Yes, limited a little 1
3 No, not limited at all 0
17. Emotional problems limit work or activities‡ 1 Yes, limited a lot 1
2 Yes, limited a little 1
3 No, not limited at all 0
18. Physical or emotional health interferes with social activities‡ 1 All of the time 1
2 Most of the time 1
3 A good bit of the time 1
4 Some of the time 1
5 A little of the time 0
6 None of the time 0
(continued on following page)
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Table A1. Items and Scoring for Frailty Index (continued)
Item Value Format Score
19. Physical health results in accomplishing less‡ 1 Yes, limited a lot 1
2 Yes, limited a little 1
3 No, not limited at all 0
20. Emotional problems result in accomplishing less‡ 1 Yes, limited a lot 1
2 Yes, limited a little 1
3 No, not limited at all 0
21. Have a lot of energy‡ 1 All of the time 0
2 Most of the time 0
3 A good bit of the time 0
4 Some of the time 0.5
5 A little of the time 1
6 None of the time 1
22. Feel downhearted or blue‡ 1 All of the time 1
2 Most of the time 1
3 A good bit of the time 1
4 Some of the time 0.5
5 A little of the time 0
6 None of the time 0
23. Feel calm or peaceful‡ 1 All of the time 0
2 Most of the time 0
3 A good bit of the time 0
4 Some of the time 0.5
5 A little of the time 1
6 None of the time 1
24. Heart disease comorbidity23† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
25. Stroke comorbidity23† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
26. Diabetes comorbidity23† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
27. Arthritis, rheumatism, or other connective tissue disorder
comorbidity†
0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
28. Emphysema, chronic bronchitis, or asthma comorbidity† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
29. Chronic liver or kidney disease comorbidity† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
30. Other cancer/leukemia comorbidity† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
31. Glaucoma, cataracts, or decreased vision comorbidity† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
(continued on following page)
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Table A1. Items and Scoring for Frailty Index (continued)
Item Value Format Score
32. Blood pressure comorbidity† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1
33. Osteoporosis comorbidity† 0 No 0
1 Not at all 1
2 Somewhat 1
3 A great deal 1




5 Totally blind 1




5 Totally deaf 1
Song X et al: J Am Geriatr Soc 58:681-687, 2010.
†Fillenbaum GG et al: J Gerontol 36:428-434, 1981.
‡Ware J et al: Med Care 34:220-233, 1996.
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